Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

CITIUS ONCOLOGY, INC.

24% ORR (5 partial responses) among 21 efficacy-evaluable patients with recurrent/refractory gynecologic malignancies.
33% ORR in endometrial cancer patients previously treated with checkpoint inhibitors; one response >3 years.
Median PFS of 20.5 months among 10 patients achieving clinical benefit (48% of evaluable patients).
Safety manageable: only 1 reversible Grade 3 capillary leak syndrome at highest dose; no new safety signals.
Phase 2 expansion study planned to further evaluate combination in gynecologic cancers including less heavily pre-treated patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.